Prywatna Praktyka Lekarska Anna Chudoba
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The research at Prywatna Praktyka Lekarska Anna Chudoba focuses on heart failure with preserved or mildly reduced ejection fraction, aiming to improve symptoms and physical function.
- Evaluation of anti‑inflammatory therapy in heart failure
- Assessment of major adverse cardiovascular event outcomes
- Investigation of novel agents for HFpEF/HFmrEF
These studies seek to test new treatments that could reduce hospitalizations and improve quality of life for patients with cardiovascular disease.
Nutritional and Metabolic Diseases
Clinical investigations address the link between obesity, systemic inflammation, and heart failure, exploring how metabolic health influences cardiovascular risk.
- Impact of weight management on heart failure outcomes
- Role of metabolic inflammation in cardiovascular health
- Testing therapies targeting obesity and systemic inflammation
The work supports the development of integrated approaches that combine metabolic control with standard heart failure care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novo Nordisk A/S2active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S5trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Prywatna Praktyka Lekarska Anna Chudoba
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 3 | Unknown | 2023-02-28 | 2026-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.